Physician profile
Gracy Joshua
NPI 1942254768
$3,184.82
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,427 · 2020: $757.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $390.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $387.69 | 2019-2020 | |
| Seagen INC. | $314.67 | 2019-2020 | |
| Pfizer INC. | $283.89 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $260.52 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $183.04 | 2019-2020 | |
| Radius Health, INC. | $171.98 | 2019-2020 | |
| Lilly USA, LLC | $150.38 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $149.71 | 2019 | |
| Tersera Therapeutics LLC | $130.46 | 2019 | |
| Genzyme Corporation | $102.62 | 2019-2020 | |
| Ucb, INC. | $95.66 | 2019-2020 | |
| Daiichi Sankyo INC. | $66.31 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $64.39 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.86 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Institutional INC. | $62.14 | 2019 | |
| Mallinckrodt Enterprises LLC | $36.11 | 2019 | |
| Celgene Corporation | $34.75 | 2019 | |
| Genentech USA, INC. | $34.61 | 2019 | |
| Amag Pharmaceuticals, INC. | $32.62 | 2019-2020 | |
| Janssen Biotech, INC. | $26.64 | 2019 | |
| Astellas Pharma US INC | $21.05 | 2019 | |
| Fortovia Therapeutics, INC. | $19.52 | 2019 | |
| Incyte Corporation | $18.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.00 | 2020 | |
| Eisai INC. | $17.84 | 2019 | |
| Puma Biotechnology, INC. | $16.83 | 2019 | |
| Dova Pharmaceuticals | $16.22 | 2019 | |
| Horizon Therapeutics Plc | $14.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gracy Joshua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.